Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.40 |
| ▸ | TSHR | P16473 | 5/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4515626 | 0.78 | SIGMAR1 (0.43) | CYP3A4CYP2D6CYP2C9TSHRHIF1A | |
| SCHEMBL7257750 | 0.78 | SIGMAR1 (0.38) | CYP3A4CYP2D6CYP2C9TSHRHIF1A | |
| SCHEMBL6078489 | 0.77 | F10 (0.44) | CYP3A4CYP2D6CYP2C9TSHRHIF1A | |
| SCHEMBL7257472 | 0.76 | CYP3A4 (0.35) | CYP3A4CYP2D6CYP2C9TSHRHIF1A | |
| SCHEMBL7257661 | 0.76 | SIGMAR1 (0.47) | CYP2D6TSHR | |
| SCHEMBL7257170 | 0.76 | CYP3A4 (0.49) | CYP3A4CYP2D6CYP2C9TSHRHIF1A | |
| SCHEMBL6080063 | 0.76 | F10 (0.44) | CYP3A4CYP2D6CYP2C9TSHRHIF1A | |
| SCHEMBL7261956 | 0.75 | F10 (0.42) | CYP3A4CYP2D6CYP2C9TSHRHIF1A | |
| SCHEMBL7263014 | 0.74 | ITGB3 (0.41) | CYP3A4CYP2D6CYP2C9TSHRHIF1A | |
| SCHEMBL15489294 | 0.74 | F10 (0.50) | CYP3A4CYP2D6CYP2C9TSHRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063716-A1 | Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1346994-A1 | CHOLESTEROL BIOSYNTHESIS INHIBITORS CONTAINING AS THE ACTIVE INGREDIENT TRICYCLIC SPIRO COMPOUNDS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063716-A1 | Cholesterol biosynthesis inhibitors containing as the active ingredient tricyclic spiro compounds | VKORC1, CYP46A1, TFPI | CYP3A4 166/4885CYP2D6 301/4885CYP2C9 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.